|
|
|
|
| LEADER |
05891nma a2201225 u 4500 |
| 001 |
EB001963357 |
| 003 |
EBX01000000000000001126259 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
210512 ||| eng |
| 020 |
|
|
|a books978-3-03921-153-1
|
| 020 |
|
|
|a 9783039211531
|
| 020 |
|
|
|a 9783039211524
|
| 100 |
1 |
|
|a Murray-Stewart, Tracy
|
| 245 |
0 |
0 |
|a Polyamine Metabolism in Disease and Polyamine-Targeted Therapies
|h Elektronische Ressource
|
| 260 |
|
|
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2019
|
| 300 |
|
|
|a 1 electronic resource (240 p.)
|
| 653 |
|
|
|a ornithine decarboxylase
|
| 653 |
|
|
|a spermine
|
| 653 |
|
|
|a transglutaminase
|
| 653 |
|
|
|a polyamine analogs
|
| 653 |
|
|
|a aging
|
| 653 |
|
|
|a tumor immunity
|
| 653 |
|
|
|a Drosophila imaginal discs
|
| 653 |
|
|
|a CRISPR
|
| 653 |
|
|
|a immunity
|
| 653 |
|
|
|a mutant BRAF
|
| 653 |
|
|
|a antizyme 1
|
| 653 |
|
|
|a capsule
|
| 653 |
|
|
|a protein synthesis in cancer
|
| 653 |
|
|
|a X-linked intellectual disability
|
| 653 |
|
|
|a cell differentiation
|
| 653 |
|
|
|a DFMO
|
| 653 |
|
|
|a Snyder-Robinson Syndrome
|
| 653 |
|
|
|a difluoromethylorthinine
|
| 653 |
|
|
|a skeletal muscle
|
| 653 |
|
|
|a spermidine/spermine N1-acetyl transferase
|
| 653 |
|
|
|a hirsutism
|
| 653 |
|
|
|a epigenetics
|
| 653 |
|
|
|a MYC
|
| 653 |
|
|
|a antizyme
|
| 653 |
|
|
|a African sleeping sickness
|
| 653 |
|
|
|a autoimmunity
|
| 653 |
|
|
|a eflornithine
|
| 653 |
|
|
|a polyamines
|
| 653 |
|
|
|a polyamine transport
|
| 653 |
|
|
|a bis(ethyl)polyamine analogs
|
| 653 |
|
|
|a spermine synthase
|
| 653 |
|
|
|a T-lymphocytes
|
| 653 |
|
|
|a pneumococcal pneumonia
|
| 653 |
|
|
|a eosinophils
|
| 653 |
|
|
|a chemoprevention
|
| 653 |
|
|
|a NF-?B
|
| 653 |
|
|
|a ?-difluoromethylornithine
|
| 653 |
|
|
|a breast cancer
|
| 653 |
|
|
|a untranslated region
|
| 653 |
|
|
|a transgenic mouse
|
| 653 |
|
|
|a colorectal cancer
|
| 653 |
|
|
|a B-lymphocytes
|
| 653 |
|
|
|a Biology, life sciences / bicssc
|
| 653 |
|
|
|a difluoromethylornithine
|
| 653 |
|
|
|a curcumin
|
| 653 |
|
|
|a cancer
|
| 653 |
|
|
|a carcinogenesis
|
| 653 |
|
|
|a polyamine transport inhibitor
|
| 653 |
|
|
|a airway smooth muscle cells
|
| 653 |
|
|
|a MCF-7 cells
|
| 653 |
|
|
|a polyphenol
|
| 653 |
|
|
|a proteomics
|
| 653 |
|
|
|a polyamine transport system
|
| 653 |
|
|
|a melanoma
|
| 653 |
|
|
|a transgenic mice
|
| 653 |
|
|
|a atrophy
|
| 653 |
|
|
|a M2 macrophages
|
| 653 |
|
|
|a human embryonic kidney 293 (HEK293)
|
| 653 |
|
|
|a complementation
|
| 653 |
|
|
|a Streptococcus pneumoniae
|
| 653 |
|
|
|a autophagy
|
| 653 |
|
|
|a neuroblastoma
|
| 653 |
|
|
|a polyamine metabolism
|
| 653 |
|
|
|a oxidative stress
|
| 653 |
|
|
|a antizyme inhibitors
|
| 653 |
|
|
|a cadaverine
|
| 653 |
|
|
|a osteosarcoma
|
| 653 |
|
|
|a mast cells
|
| 653 |
|
|
|a pancreatic ductal adenocarcinoma
|
| 653 |
|
|
|a metabolism
|
| 653 |
|
|
|a putrescine
|
| 653 |
|
|
|a polyamine
|
| 653 |
|
|
|a protein expression
|
| 653 |
|
|
|a spermine oxidase
|
| 653 |
|
|
|a diferuloylmethane
|
| 653 |
|
|
|a spermidine
|
| 653 |
|
|
|a neutrophils
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by-nc-nd/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-03921-153-1
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/56626
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/1582
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 380
|
| 520 |
|
|
|a The correlation between elevated polyamine levels and cancer is well established, and ornithine decarboxylase, the rate-limiting biosynthetic enzyme in the production of putrescine, is a bona fide transcriptional target of the Myc oncogene. Furthermore, induced polyamine catabolism contributes to carcinogenesis that is associated with certain forms of chronic infection and/or inflammation through the production of reactive oxygen species. These and other characteristics specific to cancer cells have led to the development of polyamine-based agents and inhibitors aimed at exploiting the polyamine metabolic pathway for chemotherapeutic and chemopreventive benefit. In addition to cancer, polyamines are involved in the pathologies of neurodegenerative diseases including Alzheimer's and Parkinson's, parasitic and infectious diseases, wound healing, ischemia/reperfusion injuries, and certain age-related conditions, as polyamines are known to decrease with age.
|
| 520 |
|
|
|a Polyamines are ubiquitous polycations essential for all cellular life. The most common polyamines in eukaryotes, spermine, spermidine, and putrescine, exist in millimolar intracellular concentrations that are tightly regulated through biosynthesis, catabolism, and transport. Polyamines interact with, and regulate, negatively charged macromolecules, including nucleic acids, proteins, and ion channels. Accordingly, alterations in polyamine metabolism affect cellular proliferation and survival through changes in gene expression and transcription, translation, autophagy, oxidative stress, and apoptosis. Dysregulation of these multifaceted polyamine functions contribute to multiple disease processes, thus their metabolism and function have been targeted for preventive or therapeutic intervention.
|
| 520 |
|
|
|a As in cancer, polyamine-based therapies for these conditions are an area of active investigation. With recent advances in immunotherapy, interest has increased regarding polyamine-associated modulation of immune responses, as well as potential immunoregulation of polyamine metabolism, the results of which could have relevance to multiple disease processes. The goal of this Special Issue of Medical Sciences is to present the most recent advances in polyamine research as it relates to health, disease, and/or therapy.
|